Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Rhea-AI Summary

Revolution Medicines (Nasdaq:RVMD) will present nine oral and poster presentations at the AACR Annual Meeting, April 17–22, 2026 in San Diego. Highlights include Phase 1 zoldonrasib (G12D) data in KRAS G12D NSCLC (plenary) and Phase 1/2 daraxonrasib datasets in first-line metastatic PDAC (mini-symposium).

Presentations also cover a new class of catalytic RAS(ON) inhibitors addressing emergent resistance and multiple preclinical and clinical RAS(ON) research topics.

Key Figures

AACR presentations: 9 presentations AACR meeting dates: April 17–22, 2026 Plenary session slot: Phase 1 zoldonrasib NSCLC data +2 more

5 metrics

AACR presentations 9 presentations Oral and poster presentations across RAS(ON) pipeline at AACR 2026

AACR meeting dates April 17–22, 2026 American Association for Cancer Research Annual Meeting

Plenary session slot Phase 1 zoldonrasib NSCLC data Featured in plenary session at AACR 2026

Program stages Phase 1 and Phase 1/2 Zoldonrasib and daraxonrasib datasets to be presented

RASolve 301 phase Phase 3 study Daraxonrasib vs docetaxel in RAS-mutant NSCLC

Market Reality Check

Price: $99.00 Vol: Volume 1,865,364 vs 20-da...

normal vol

$99.00 Last Close

Volume Volume 1,865,364 vs 20-day avg 2,304,368; relative volume at 0.81x indicates typical trading activity. normal

Technical Price 99.13 is trading above the 200-day MA of 63.71 and sits 20.37% below the 52-week high and 239.84% above the 52-week low.

Peers on Argus

RVMD showed a small gain of 0.13% while peers like MRNA (0.8%), MDGL (0.72%) and...

RVMD showed a small gain of 0.13% while peers like MRNA (0.8%), MDGL (0.72%) and ROIV (0.32%) were also modestly positive, but no names appeared on the momentum scanner, suggesting stock-specific rather than sector-driven action.

Historical Context

5 past events · Latest: Feb 25 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 25	Earnings and update	Negative	-1.5%	Reported large 2025 net loss alongside high R&D and G&A spending.
Feb 24	Conference participation	Neutral	-1.5%	Announced CEO fireside chat at TD Cowen health care conference.
Feb 18	Earnings date set	Neutral	+3.0%	Scheduled Q4 and full-year 2025 earnings release and webcast.
Feb 04	Investor summit	Neutral	-0.4%	CEO to speak at Guggenheim biotech summit with webcast access.
Jan 29	Clinical trial start	Positive	+0.9%	Dosed first patient in RMC-5127-001 first-in-human RAS(ON) G12V study.

Pattern Detected

Across recent earnings, conference, and clinical updates, RVMD’s share reactions have generally moved in the same direction as the perceived news tone, with no clear pattern of selling on good news or buying on bad news.

Recent Company History

Over the last few months, Revolution Medicines has balanced heavy investment with expanding clinical activity. On Jan 29, 2026, it dosed the first patient with RMC-5127, its fifth disclosed mutant-selective RAS(ON) inhibitor, targeting RAS G12V–driven cancers. Multiple conference participations in February 2026 maintained visibility with investors. On Feb 25, 2026, RVMD reported Q4 and full-year 2025 results, highlighting $2.0 billion in cash, a $250 million royalty tranche and full-year 2025 net loss of $1.1B. Today’s AACR-focused announcement continues that theme of broad RAS(ON) pipeline execution.

Market Pulse Summary

This announcement highlights RVMD’s breadth in RAS(ON)-targeted oncology, with nine AACR presentatio...

Analysis

This announcement highlights RVMD’s breadth in RAS(ON)-targeted oncology, with nine AACR presentations spanning Phase 1, Phase 1/2, and Phase 3 efforts in NSCLC and pancreatic cancer. Combined with earlier milestones like first dosing of RMC-5127 and multiple ongoing pivotal trials, the news underscores a broad, capital-intensive pipeline strategy. Investors may watch the quality of AACR data, progress in Phase 3 programs, and future regulatory updates to gauge how this scientific momentum translates into value.

Key Terms

ras(on), non-small cell lung cancer, nsclc, pancreatic ductal adenocarcinoma (pdac), +3 more

7 terms

ras(on) medical

"advances across its RAS(ON) inhibitor pipeline will be featured at the"

A RAS (oncogene) is a family of genes that act like a cell’s growth switch; when they work normally they help cells respond to signals, but certain mutations can make the switch stuck in the ‘on’ position and drive uncontrolled cell growth. Investors watch RAS closely because mutations are common drivers of many cancers, and drugs that can safely target or correct RAS-driven growth can become major commercial opportunities or affect the value of companies developing such therapies.

non-small cell lung cancer medical

"KRAS G12D mutant non-small cell lung cancer, which will be featured"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

nsclc medical

"Non-Small Cell Lung Cancer (NSCLC)"

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

pancreatic ductal adenocarcinoma (pdac) medical

"first line metastatic pancreatic ductal adenocarcinoma (PDAC), including"

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, arising in the cells that line the small ducts which carry digestive juices. It behaves aggressively and is often diagnosed late, like a clogged pipe that causes widespread damage before it’s noticed. For investors, PDAC matters because its poor prognosis and limited approved treatments create a large unmet medical need—meaning successful new therapies can bring significant returns but carry high clinical and regulatory risk.

phase 1 medical

"include new Phase 1 data for zoldonrasib, a RAS(ON) G12D-selective"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

phase 2 medical

"present two Phase 1/2 datasets evaluating daraxonrasib, a RAS(ON)"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

phase 3 medical

"RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) vs."

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. Not financial advice.

REDWOOD CITY, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster presentations highlighting advances across its RAS(ON) inhibitor pipeline will be featured at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 17–22, 2026 in San Diego.

The presentations will include new Phase 1 data for zoldonrasib, a RAS(ON) G12D-selective inhibitor, in patients with previously treated KRAS G12D mutant non-small cell lung cancer, which will be featured in a plenary session.

The company will also present two Phase 1/2 datasets evaluating daraxonrasib, a RAS(ON) multi-selective inhibitor, in patients with first line metastatic pancreatic ductal adenocarcinoma (PDAC), including monotherapy data and daraxonrasib plus chemotherapy combination data, the latter of which will be featured in a mini-symposium session.

Additional presentations will highlight preclinical research supporting a new class of mutant-targeted catalytic RAS(ON) inhibitors, designed to maintain antitumor activity in the setting of emergent resistance.

Together, these presentations reflect the breadth of Revolution Medicines’ RAS(ON)-focused development strategy, spanning clinical studies across multiple tumor types and ongoing discovery efforts to address resistance and expand therapeutic opportunities for patients with RAS-driven cancers.

Details of the presentations are listed below.

Revolution Medicines Invited Presentation:

Title:	Targeting the Oncogenic State of RAS: Lessons from Tri-Complex Inhibitors
Presenter:	Mallika Singh, Ph.D., Revolution Medicines
Session:	How KRAS Inhibitors Got to the Clinic: From Discovery to Patient Benefit
Date/Time:	April 18; 3:00 p.m. – 3:20 p.m. PST

Revolution Medicines Oral Presentation:

Title:	Preliminary Safety and Clinical Activity of Zoldonrasib (RMC-9805), an Oral, RAS(ON) G12D-Selective, Tri-Complex Inhibitor in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer (NSCLC)
Presenter:	Jonathan Reiss, M.D., UC Davis Comprehensive Cancer Center
Abstract Number:	CT021
Session:	New Frontiers in Precision Oncology
Date/Time:	April 19; 1:30 p.m. – 1:45 p.m. PST

Revolution Medicines Mini Symposiums:

Title:	Daraxonrasib plus Chemotherapy as First Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma (mPDAC)
Presenter:	Brian Wolpin, M.D., Dana-Farber Cancer Institute
Abstract Number:	LB407
Session:	Late-Breaking Research
Date/Time:	April 21; 4:05 p.m. – 4:20 p.m. PST

Title:	Discovery of a New Class of Mutant-Targeted Catalytic RAS(ON) Inhibitors with Retained Antitumor Activity in Setting of Emergent Resistance Due to Elevated RAS Flux
Presenter:	Jacqueline (Jan) Smith, Ph.D., Revolution Medicines
Abstract Number:	6782
Session:	Targeted Protein Degradation and Non-canonical Oncogenic Signaling
Date/Time:	April 21; 4:05 p.m. – 4:20 p.m. PST

Revolution Medicines Posters:

Title:	RAS(ON) Inhibition in both Cancer and Immune Cells by Daraxonrasib Drives Antitumor Immunity
Presenter:	Nataliya Shifrin, Ph.D., Revolution Medicines
Abstract Number:	2831
Session:	Immune Mechanisms Invoked by Other Therapies and Exposures
Date/Time:	April 20; 2:00 p.m. – 5:00 p.m. PST

Title:	RASolve 301: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in Patients with Previously Treated RAS-mutant NSCLC
Presenter:	Ferdinandos Skoulidis, M.D., Ph.D., MRCP, MD Anderson Cancer Center
Abstract Number:	CT215
Session:	Late-Breaking Research
Date/Time:	April 21; 9:00 a.m. – 12:00 p.m. PST

Title:	Daraxonrasib Monotherapy as First Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
Presenter:	Eileen O’Reilly, M.D., Memorial Sloan Kettering Cancer Center
Abstract Number:	LB337
Session:	Late-Breaking Research: Clinical Research 3
Date/Time:	April 21; 2:00 p.m. – 5:00 p.m. PST

Title:	RAS(ON) Multi-Selective Inhibitors Stimulate the Hydrolysis of RAS-GTP to RAS-GDP and Drive Synergistic Combination Benefit with KRAS(OFF) Inhibitors in G12 Mutant Tumors
Presenter:	Kyle Seamon, Ph.D., Revolution Medicines
Abstract Number:	5696
Session:	Mechanisms of Anticancer Drug Action
Date/Time:	April 21; 2:00 p.m. – 5:00 p.m. PST

Collaborator Mini Symposium:

Title:	Active RAS Inhibition Intercepts Pancreas Cancer in Mice
Presenter:	Ben Stanger, M.D., Ph.D., Penn Pancreatic Cancer Research Center
Abstract Number:	LB406
Session:	Late-Breaking Research
Date/Time:	April 21; 3:50 p.m. – 4:05 p.m. PST

About Revolution Medicines, Inc.
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C). For more information, please visit www.revmed.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation statements regarding the company’s development strategy and its ability to build or advance its portfolio and R&D pipeline; progression of clinical studies and findings from these studies, including the tolerability, safety, and potential efficacy of the company’s candidates being studied; and the ability of the company’s RAS(ON) inhibitors to maintain antitumor activity in the setting of emergent resistance.

Forward-looking statements are typically, but not always, identified by the use of words such as “aims,” “anticipate,” "believe," "estimate," "expect," "plan," “potential,” “project,” “up to,” "will" and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause the company’s development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including the company’s programs’ development stages, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, the company’s ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of the company’s capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape, and the effects on the company’s business of the global events, such as international conflicts or global pandemics. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Revolution Medicines in general, see Revolution Medicines’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on February 25, 2026, and its future periodic reports to be filed with the SEC. Except as required by law, Revolution Medicines undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances, or to reflect the occurrence of unanticipated events.

Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com

FAQ

What does Revolution Medicines (RVMD) present about zoldonrasib at AACR 2026?

The company will present new Phase 1 safety and clinical activity data for zoldonrasib in KRAS G12D NSCLC in a plenary session. According to the company, this oral G12D-selective tri-complex inhibitor data will be discussed April 19 during the New Frontiers in Precision Oncology session.

When and where will Revolution Medicines (RVMD) present daraxonrasib plus chemotherapy data at AACR 2026?

Daraxonrasib plus chemotherapy first-line metastatic PDAC data will be presented April 21 in a mini-symposium Late-Breaking Research session. According to the company, the presentation is scheduled for April 21 at 4:05 p.m. PST during the Late-Breaking Research program.

What clinical programs will Revolution Medicines (RVMD) feature across AACR 2026 presentations?

RVMD will feature daraxonrasib (multi-selective), zoldonrasib (G12D-selective), and other RAS(ON) clinical candidates. According to the company, presentations span Phase 1, Phase 1/2, and Phase 3 clinical datasets plus preclinical research addressing resistance.

Will Revolution Medicines (RVMD) present research on resistance to RAS inhibitors at AACR 2026?

Yes. The company will present discovery data on a new class of catalytic RAS(ON) inhibitors retaining antitumor activity amid emergent resistance. According to the company, that research addresses elevated RAS flux and is scheduled in a targeted signaling session on April 21.

Are there any Phase 3 trials from Revolution Medicines (RVMD) discussed at AACR 2026?

A Phase 3 study, RASolve 301 of daraxonrasib versus docetaxel in previously treated RAS-mutant NSCLC, is included as a poster presentation. According to the company, the abstract appears in a Late-Breaking Research poster session on April 21.

How can investors follow Revolution Medicines (RVMD) AACR 2026 presentations and timing?

Key presentation dates include April 18–21, 2026 with scheduled plenary, mini-symposium, oral, and poster slots. According to the company, detailed abstracts and session times are listed for AACR events between April 17 and April 22 in San Diego.